Research trends on platelet-rich plasma in improving ovarian dysfunction: A bibliometric and visualization analysis

富血小板血浆改善卵巢功能障碍的研究趋势:文献计量学和可视化分析

阅读:2

Abstract

INTRODUCTION: Platelet-rich plasma (PRP) has attracted attention due to its potential to restore or enhance ovarian function. However, resources for evaluating the research trends of PRP in improving ovarian dysfunction are limited. This study aims to conduct a bibliometric analysis of the relevant literature on PRP improving ovarian dysfunction, and explore the current research status, hotspots and frontiers in this field. METHODS: Studies on PRP improving ovarian dysfunction were retrieved from the Science Citation Index Extended (SCI-E) database of Web of Science (WOS). The research trends and characteristics were analyzed using visualization software such as VOSviewer, SCImago Graphica and CiteSpace. RESULTS: A total of 193 studies were identified. The USA, IRAN and CHINA were the most productive countries. The number of publications on PRP improving ovarian dysfunction has shown a significant upward trend since 2018. Papers published in the United States lead in terms of the number of publications, citation counts and H-index. Although the number of publications in Turkey is slightly lower than that in China, its H-index and average citations are higher than those in China. The strongest keyword is "stimulation", and the keyword with the longest duration of an outbreak is "gonadotropins" (starting in 2010 and ending in 2018). The 5 largest co-citation clusters are as follows: menopause (#0), fertility preservation (#1), implantation failure (#3), preimplantation genetic testing (#4), stem cell therapy (#5). CONCLUSIONS: Current research indicates that there is still great potential for the development of PRP in improving ovarian dysfunction. In the future, it is necessary to break through the current bottleneck, promote the transformation of PRP from a "potential intervention method" to a "clinical routine plan", and provide safer and more effective treatment options for patients with decreased ovarian dysfunction and assisted reproduction.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。